GSK, MorphoSys RA therapy misses in Phase IIb

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said GSK3196165 (formerly MOR103) plus methotrexate missed the primary endpoint in the Phase IIb BAROQUE trial to treat moderate to severe rheumatoid arthritis in patients who had an inadequate

Read the full 330 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE